Evidence map›Paper›PMID 28368383›Full record

ArticleNature medicine2017

Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor-neutralizing therapy in patients with inflammatory bowel disease.

Nathaniel R West, Ahmed N Hegazy, Benjamin M J Owens, Samuel J Bullers, Bryan Linggi, Sofia Buonocore, Margherita Coccia, Dieter Görtz, Sébastien This, Krista Stockenhuber and 16 more

Erratum issued Registry-linked trialOpen access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT03765450 (Pharmacokinetics of Infliximab and Tumor Necrosis Factor Concentrations in Serum, Stool, and Colonic Mucosa in Acute Severe Ulcerative Colitis), which is not on this map. Cited by 490 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
490citing papers in PubMed, 1 pooled it
53.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03765450 active not recruitingnot on this mapstarted 2018, after this paper: background citation

Pharmacokinetics of Infliximab and Tumor Necrosis Factor Concentrations in Serum, Stool, and Colonic Mucosa in Acute Severe Ulcerative Colitis

TypeobservationalSponsorAlimentiv Inc.Ran2018 to 2027Enrolled18ConditionsUlcerative ColitisArmsInfliximab
3 · Its place in the literature

Who cites it

490 citing papers in PubMed, 1 synthesis or guideline pooled it, 772 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Article
  6. Inflammatory bowel disease and breast cancer: epidemiological evidence, shared biology, and clinical management.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2026
    Review
  7. Article
  8. iScience · 2026
    Article
  9. Article
  10. Review
  11. Identification of Ferro-Aging-Related Biomarkers for Ulcerative Colitis Through Integrated Machine Learning, Single-Cell Analysis, and Spatial Transcriptomics.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026
    Article
  12. Review
  13. Article
  14. Review
  15. Review
  16. Review
  17. Article
  18. Fibroblasts resistScience advances · 2026
    Article
  19. Review
  20. Review

430 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

26 authors at 5 institutions in 3 countries.

Nathaniel R WestKennedy Institute of Rheumatology, University of Oxford, Oxford, UK.ORCID http://orcid.org/0000-0001-9991-0503
Ahmed N HegazyKennedy Institute of Rheumatology, University of Oxford, Oxford, UK.
Benjamin M J OwensSomerville College, University of Oxford, Oxford, UK.
Samuel J BullersKennedy Institute of Rheumatology, University of Oxford, Oxford, UK.
Bryan LinggiJanssen Research and Development, Raritan, New Jersey, USA.
Sofia BuonocoreSir William Dunn School of Pathology, University of Oxford, Oxford, UK.
Margherita CocciaSir William Dunn School of Pathology, University of Oxford, Oxford, UK.
Dieter GörtzInstitute of Biochemistry and Molecular Biology, RWTH Aachen University, Aachen, Germany.
Sébastien ThisTranslational Gastroenterology Unit, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
Krista StockenhuberKennedy Institute of Rheumatology, University of Oxford, Oxford, UK.
Johanna PottSir William Dunn School of Pathology, University of Oxford, Oxford, UK.
Matthias FriedrichKennedy Institute of Rheumatology, University of Oxford, Oxford, UK.
Grigory RyzhakovKennedy Institute of Rheumatology, University of Oxford, Oxford, UK.
Frédéric BaribaudJanssen Research and Development, Raritan, New Jersey, USA.
Carrie BrodmerkelJanssen Research and Development, Raritan, New Jersey, USA.
Constanze CieluchMedical Department, Division of Gastroenterology, Infectiology and Rheumatology, Charité-Universitätsmedizin Berlin, Germany.
Nahid RahmanOPPF-UK, The Research Complex at Harwell, Rutherford Appleton Laboratory, Harwell, Oxford, UK.
Gerhard Müller-NewenInstitute of Biochemistry and Molecular Biology, RWTH Aachen University, Aachen, Germany.
Raymond J OwensOPPF-UK, The Research Complex at Harwell, Rutherford Appleton Laboratory, Harwell, Oxford, UK.
Anja A KühlMedical Department, Division of Gastroenterology, Infectiology and Rheumatology, Charité-Universitätsmedizin Berlin, Germany.
Kevin J MaloySir William Dunn School of Pathology, University of Oxford, Oxford, UK.
Scott E PlevyJanssen Research and Development, Raritan, New Jersey, USA.
Oxford IBD Cohort Investigators
Satish KeshavTranslational Gastroenterology Unit, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
Simon P L TravisTranslational Gastroenterology Unit, Nuffield Department of Medicine, University of Oxford, Oxford, UK.ORCID http://orcid.org/0000-0002-2690-4361
Fiona PowrieKennedy Institute of Rheumatology, University of Oxford, Oxford, UK.
University of Oxford · GBJanssen (United States) · USRutherford Appleton Laboratory · GBCentre for Human Genetics · GBResearch Complex at Harwell · GB

Funding

Department of Health NIHR-RP-R3-12-026Medical Research Council G0200231Medical Research Council MC_UU_00008/7Medical Research Council MC_UU_12010/7Medical Research Council MR/K018779/1Medical Research Council MR/N02690X/1Wellcome Trust 109965/Z/15/Z
6 · The paper itself

Abstract

Inflammatory bowel diseases (IBD), including Crohn's disease (CD) and ulcerative colitis (UC), are complex chronic inflammatory conditions of the gastrointestinal tract that are driven by perturbed cytokine pathways. Anti-tumor necrosis factor-α (TNF) antibodies are mainstay therapies for IBD. However, up to 40% of patients are nonresponsive to anti-TNF agents, which makes the identification of alternative therapeutic targets a priority. Here we show that, relative to healthy controls, inflamed intestinal tissues from patients with IBD express high amounts of the cytokine oncostatin M (OSM) and its receptor (OSMR), which correlate closely with histopathological disease severity. The OSMR is expressed in nonhematopoietic, nonepithelial intestinal stromal cells, which respond to OSM by producing various proinflammatory molecules, including interleukin (IL)-6, the leukocyte adhesion factor ICAM1, and chemokines that attract neutrophils, monocytes, and T cells. In an animal model of anti-TNF-resistant intestinal inflammation, genetic deletion or pharmacological blockade of OSM significantly attenuates colitis. Furthermore, according to an analysis of more than 200 patients with IBD, including two cohorts from phase 3 clinical trials of infliximab and golimumab, high pretreatment expression of OSM is strongly associated with failure of anti-TNF therapy. OSM is thus a potential biomarker and therapeutic target for IBD, and has particular relevance for anti-TNF-resistant patients.

Indexed as

AdultAgedAnimalsAntibodies, MonoclonalCase-Control StudiesChemokinesColitisDisease Models, AnimalFemaleFlow CytometryGastrointestinal AgentsGene Expression ProfilingHumansImmunoblottingImmunohistochemistryInflammationAntibodies, MonoclonalChemokinesGastrointestinal AgentsgolimumabIL6 protein, humanInfliximabIntercellular Adhesion Molecule-1Interleukin-6Oncostatin MOncostatin M Receptor beta SubunitOSM protein, humanOsm protein, mouseOSMR protein, humanOsmr protein, mouseTumor Necrosis Factor-alpha

Identifiers

PMID28368383
PMCPMC5420447
OpenAlexW2604780989

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.